Based on prior knowledge, characterizing the effect of baseline severity, genetic variants (e.g., glucocerebrosidase) and concomitant PD medications, for instance, in the intrinsic rate of disease progression may further inform patient selection in PD trials. Here, GBA1 is linked to Parkinson disease.